Merida Biosciences
Adam Townsend has extensive experience in the biotechnology and pharmaceutical industries, currently serving as Chief Executive Officer at Merida Biosciences since March 2025. Prior roles include Chief Operating Officer and Chief Commercial Officer at Apellis Pharmaceuticals from November 2018 to March 2025. Adam’s tenure at Biogen spanned eight years, during which various senior leadership positions were held, including Senior Vice President of Corporate Development and Senior Vice President for the Specialty Medicines and Rare Disease Group. Additional experience includes key marketing and managerial roles at EUSA Pharma and Amgen, and starting a career as a Specialist Representative at Novartis. Adam Townsend earned a degree from the Royal Holloway, University of London between 1994 and 1997.
This person is not in any teams
This person is not in any offices
Merida Biosciences
Merida Biosciences is a biotechnology company pioneering a new class of precision therapeutics designed to selectively and durably eliminate pathogenic antibodies that drive disease. The company is advancing a robust pipeline to precisely eliminate the root cause of multiple autoimmune and allergic conditions that are inadequately treated today. Its lead program is designed to specifically and rapidly clear the pathogenic autoantibodies that cause Graves' disease, an autoimmune disorder that affects the thyroid gland. Merida was publicly launched in April 2025 and is based in Cambridge, MA. For more information about Merida, visit www.meridabio.com.